ट्रैज़ोडोन के इंटरैक्शन

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (अल्प्राज़ोलम लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (आइवाब्राडिन लेबल, चेतावनियां और सावधानियां)

RALDESY is contraindicated in patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2) , Drug Interactions (7.1) ]. (ट्रैज़ोडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (इलोपेरिडोन लेबल, दवाओं के इंटरैक्शन)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (एज़िथ्रोमाइसिन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (एज़ेलास्टिन और फ्लुटिकासोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (एम्फेटामाइन और डेक्सट्रोएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (ऑक्सालिप्लैटिन लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ओलिसेरिडिन लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (ओलोपाटाडीन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (ओलोपाटाडीन और मोमेटासोन लेबल, चेतावनियां और सावधानियां)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (कार्बामाज़ेपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (कार्बिनोक्सामिन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (केटामिन लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (कोडीन लेबल, बॉक्स्ड चेतावनी)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (क्लोनिडिन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (ज़िप्रासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (ज़ेलेप्लॉन लेबल, चेतावनियां)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (ज़ोल्पिडेम लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (टेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

RALDESY is contraindicated in patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2) , Drug Interactions (7.1) ]. (ट्रैज़ोडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (डोफेटिलाइड लेबल, चेतावनियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (थायोरिडाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (नालबुफिन लेबल, बॉक्स्ड चेतावनी)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (नाल्मेफीन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (पिमोज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (पेंटाज़ोसिन और नालोक्सोन लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (प्रोपाफेनोन लेबल, चेतावनियां और सावधानियां)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

RALDESY is contraindicated in patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2) , Drug Interactions (7.1) ]. (ट्रैज़ोडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Drugs that Prolong the QT Interval : Avoid concomitant use. (फेनोबार्बिटोन लेबल, दवाओं के इंटरैक्शन)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (फॉस्कारनेट लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (फॉस्फोमाइसिन लेबल, दवाओं के इंटरैक्शन)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (फ्लुमाज़ेनिल लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (बेलाडोना और ओपियम लेबल, बॉक्स्ड चेतावनी)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूप्रेनॉर्फिन लेबल, बॉक्स्ड चेतावनी)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (मिडाज़ोलम लेबल, बॉक्स्ड चेतावनी)

Intervention: RALDESY is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Contraindications (4) , Dosage and Administration ( 2.3 , 2.4) , and Warnings and Precautions (5.2) ]. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (मेटाक्सालोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (मेथएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (मेथाडोन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (मॉर्फिन लेबल, बॉक्स्ड चेतावनी)

RALDESY is contraindicated in patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2) , Drug Interactions (7.1) ]. (ट्रैज़ोडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (रेमिफेंटानिल लेबल, बॉक्स्ड चेतावनी)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: RALDESY is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Contraindications (4) , Dosage and Administration ( 2.3 , 2.4) , and Warnings and Precautions (5.2) ]. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (लिसडेक्सएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (लेवॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (लेवोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (लेवोसेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (वेपडेजेस्ट्रेंट लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

शराब को नींद लाने वाली दवाओं (ओपिओइड, बेंज़ोडायज़ेपिन, नींद की दवाएं, मसल रिलैक्सेंट) के साथ लेने से खतरनाक स्तर का उनींदापन, धीमी सांस और ओवरडोज़ हो सकता है। (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (सिप्रोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

सेंट जॉन्स वॉर्ट को एंटीडिप्रेसेंट और अन्य सेरोटोनर्जिक दवाओं के साथ लेने से सेरोटोनिन सिंड्रोम का जोखिम बढ़ता है। (NCCIH, St. John's Wort)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (सेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

RALDESY is contraindicated in patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2) , Drug Interactions (7.1) ]. (ट्रैज़ोडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. (सोडियम ऑक्सीबेट लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (हाइड्रॉक्सीक्लोरोक्वीन लेबल, चेतावनियां और सावधानियां)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (हाइड्रॉक्सीज़िन लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (हाइड्रोमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (आइसोप्रेनालिन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (आरफॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (आर्टिकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (इप्राट्रोपियम और सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (एरिबुलिन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations (8.5) ] . (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (कोकेन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (क्लोरोप्रोकेन लेबल, सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (गोसेरेलिन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (ग्लाइकोपाइरोलेट लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (जेफिटिनिब लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (टरब्यूटालिन लेबल, सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ट्रिप्टोरेलिन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Digoxin or Phenytoin: Monitor for increased digoxin or phenytoin serum levels ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (डेस्मोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Caution should be taken when darifenacin extended-release tablets is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants ( 7.2 ) (डैरिफेनासिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (ड्यूटेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (नालोक्सोन लेबल, चेतावनियां और सावधानियां)

…malformation, central nervous system tumor or infection, or metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia) excessive use of alcohol or sedatives, addiction to cocaine or stimulants, or withdrawal from sedatives patients with diabetes treated with insulin and/or oral diabetic medications (sulfonylureas and meglitinides)… (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (पैसिरियोटाइड लेबल, दवाओं के इंटरैक्शन)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (पोनेसिमोड लेबल, दवाओं के इंटरैक्शन)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (प्राइमाक्वीन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (प्रिलोकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (फाइसोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (फिनाइलएफ्रिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Digoxin or Phenytoin: Monitor for increased digoxin or phenytoin serum levels ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (फ्लुटिकासोन और सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (बिस्मथ सबसाइट्रेट, मेट्रोनिडाज़ोल और टेट्रासाइक्लिन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations (8.5) ] . (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Amphetamines may enhance the effects of tricyclic antidepressants. (बेंज़फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

…hydrochloride extended-release tablets (XL), concurrent administration of bupropion hydrochloride extended-release tablets (XL) and agents that lower the seizure threshold (e.g., other bupropion products, antipsychotics, antidepressants, theophylline, or systemic corticosteroids) should be undertaken only with extreme caution [see Warnings and Precautions (5.3)] . (ब्यूप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (मेटाइरोसिन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (मेट्रोनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (मेथस्कोपोलामाइन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (मेपिवाकेन लेबल, चेतावनियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (मॉक्सीफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (रिल्पिविरिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (रोक्यूरोनियम लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (लियोथायरोनिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (लेवोथायरोक्सिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (लेवोसैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ल्यूप्रोलाइड लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing RALDESY. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (वैसोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम लेबल, दवाओं के इंटरैक्शन)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (सिनाकैल्सेट लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (सुनिटिनिब लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants: RALDESY may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

Intervention: Patients should be counseled that RALDESY may enhance the response to alcohol, barbiturates, and other CNS depressants. (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (डॉक्साप्राम लेबल, चेतावनियां)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (बेंज़ट्रोपिन लेबल, चेतावनियां)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (लोवास्टेटिन लेबल, चेतावनियां)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (एंटाकैपोन लेबल, सावधानियां)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)